

1. A pharmaceutical composition comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (hereinafter 'Compound (I)', characterised in that the composition comprises 2 to 12 mg of Compound (I) in a pharmaceutically acceptable form and optionally a pharmaceutically acceptable carrier therefor.

22. A composition according to claim 1 which comprises 2 to 4mg of Compound (I) in a pharmaceutically acceptable form.

23. A composition according to claim 1 which comprises 4 to 8mg of Compound (I) in a pharmaceutically acceptable form.

24. A composition according to claim 1 which comprises 8 to 12 mg of Compound (I) in a pharmaceutically acceptable form.

25. A composition according to claim 1 which comprises 2 mg of Compound (I) in a pharmaceutically acceptable form.

26. A composition according to claim 1 which comprises 4 mg of Compound (I) in a pharmaceutically acceptable form.

27. A composition according to claim 1 which comprises 8 mg of Compound (I) in a pharmaceutically acceptable form.

28. A composition according to claim 1 which comprises the maleate salt of Compound (I)

29. A process for preparing a pharmaceutical composition comprising 2 to 12 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form and a pharmaceutically acceptable carrier therefor, which process comprises admixing 2 to 12 mg of the dione in a pharmaceutically acceptable form and the pharmaceutically acceptable carrier.

30. A process according to claim 29 wherein the composition is in unit dosage form.

31. A process according to claim 29 wherein the composition is a tablet.

32. A process for preparing a pharmaceutical composition of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form and a pharmaceutically acceptable carrier, which process comprises:

(i) preparing a first composition comprising the dione in a pharmaceutically acceptable form and a first pharmaceutically acceptable carrier;

(ii) admixing the first composition with a second pharmaceutically acceptable carrier to provide the required composition of dione and optionally thereafter formulating the composition produced into an administerable form.

33. A process according to claim 32 wherein the composition is in unit dosage form.

34. A process according to claim 32 wherein the composition is a tablet.

35. A composition comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form and optionally a pharmaceutically acceptable carrier, wherein the composition is a pharmaceutically acceptable, pre-administration composition.

36. A pre-administration composition according to claim 35 which is a concentrate of the dione in a pharmaceutically acceptable form.

37. A composition according to claim 35 adapted to be diluted with a pharmaceutically acceptable diluent so as to provide a composition for administration.

20060514-030302

38. A composition according to claim 35 which contains up to 50% by weight of the dione in a pharmaceutically acceptable form.

39. A composition according to claim 35 which contains an amount of the dione in a pharmaceutically acceptable form in the range of from 5 to 20% by weight.

40. A composition according to claim 35 which contains 5%, 10% or 15% by weight of the dione in a pharmaceutically acceptable form.

41. A composition according to claim 35, which contains Compound (I) in a pharmaceutically acceptable form, sodium starch glycollate, hydroxypropyl methylcellulose 2910, microcrystalline cellulose and lactose monohydrate.

42. A composition according to claim 35 in granular form.

200604-469001